GSK To Hand Over $227M For Basilea Eczema Drug
A GlaxoSmithKline PLC unit will get patent, trademark and distribution rights for a popular eczema drug, beefing up its skin care business in exchange for an initial payment of £146 million...To view the full article, register now.
Already a subscriber? Click here to view full article